Intravenous busulfan decreases hepatic venoocclusive disease and overall 100-day mortality versus oral busulfan as part of conditioning regimen for autologous and allogeneic stem cell transplantation in children

被引：0
|
作者：
Molina, J. R.
Gonzalez, M.
Verdeguer, A.
Martinez, A.
Badell, I.
Diaz, M. A.
Maldonado, M.
Gonzalez, E.
Munoz, A.
Gomez, P.
机构：
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S290 / S291
页数：2
相关论文
共 50 条
  • [21] Comparison of Intravenous with Oral Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Regimens for Pediatric Acute Leukemia
    Kato, Motohiro
    Takahashi, Yoshiyuki
    Tomizawa, Daisuke
    Okamoto, Yasuhiro
    Inagaki, Jiro
    Koh, Katsuyoshi
    Ogawa, Atsushi
    Okada, Keiko
    Cho, Yuko
    Takita, Junko
    Goto, Hiroaki
    Sakamaki, Hisashi
    Yabe, Hiromasa
    Kawa, Keisei
    Suzuki, Ritsuro
    Kudo, Kazuko
    Kato, Koji
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (12) : 1690 - 1694
  • [22] ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION USING INTRAVENOUS BUSULFAN IN MYELOABLATIVE AND REDUCED-INTENSITY CONDITIONING REGIMEN IN ACUTE LEUKEMIA PATIENTS. A COMPARISON ANALYSIS WITH ORAL BUSULFAN
    Sampol, A.
    Gutierrez, A.
    Ballester, C.
    Gual, C.
    Canaro, M.
    Novo, A.
    Galmes, A.
    Morey, M.
    Duran, M. A.
    Lo Rizzo, L.
    Besalduch, J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S314 - S314
  • [23] A comparison of two radiation-free regimen as conditioning for allogeneic stem cell transplantation for children with leukemia; Busulfan-melphalan vs busulfan-cyclophosphamide.
    Nozaki, C
    Matsuyama, T
    Okamura, J
    Kawa, K
    Hamamoto, K
    Sako, M
    Kikuta, A
    Tabuchi, K
    Kigasawa, T
    Kato, S
    Kojima, S
    BLOOD, 2001, 98 (11) : 197A - 197A
  • [24] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [25] Peri-Engraftment Mucositis Amongst Patients Receiving Intravenous Busulfan/Fludarabine as Conditioning Regimen for Allogeneic Hemopoietic Stem Cell Transplantation
    Deol, Abhinav
    Manickam, Palaniappan
    Uberti, Joseph
    Ratanatharathorn, Voravit
    Lum, Lawrence G.
    Ayash, Lois
    Abidi, Muneer H.
    Abrams, Judith
    Al-Kadhimi, Zaid
    BLOOD, 2009, 114 (22) : 1299 - 1299
  • [26] INTRAVENOUS BUSULFAN IN AUTOLOGOUS STEM CELL TRANSPLANTATION CONDITIONING REGIMEN FOR ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA. MULTICENTRE RETROSPECTIVE ANALYSIS
    Grande, C.
    Garcia Sanchez, P. J.
    de la Rubia, J.
    Serrano, D.
    Lopez Duarte, M.
    Garcia Boyero, R.
    Rosique, P.
    Heras, I.
    Martinez, R.
    Lahuerta, J. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 292 - 293
  • [27] Therapeutic drug monitoring of oral vs intravenous busulfan in recipients of reduced-intensity conditioning allogeneic stem cell transplantation
    Arnan, M.
    Munoz, C.
    Sancho, J. M.
    Peralta, T.
    Patino, B.
    Parody, R.
    Ribera, J. M.
    Clopes, A.
    Duarte, R. F.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S82 - S83
  • [28] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [29] Intravenous busulfan dosed four times daily or once daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation
    Shaughnessy, PJ
    Bachier, C
    Alexander, L
    Bowen, B
    LeMaistre, CF
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 28 - 28
  • [30] Less veno-occlusive disease after intravenous versus oral busulfan for autologous haematopoietic stem cell transplantation: the Belgian paediatric experience
    Huybrechts, S. J.
    Beguin, Y.
    Bordon, V.
    Dresse, M.
    Dupont, S.
    Ferster, A.
    Laureys, G.
    Meyts, I.
    Renard, M.
    Vermylen, C.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S379 - S379
12345